Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
Eligibility criteria
Qualifiers
Are an adult aged 18 or over at baseline
Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
Disqualifiers
None
Trial design
Treatments tested in this trial
- Mavacamten
Treatment groups
362 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov